Table 1 Baseline characteristics
Patient subgroups | ||||||||
|---|---|---|---|---|---|---|---|---|
Prior preventive treatment failure | Concomitant preventive | |||||||
Yes (N = 117) | No (N = 144) | Yes (N = 92) | No (N = 169) | |||||
Erenumab 70 mg (N = 59) | Placebo (N = 58) | Erenumab 70 mg (N = 71) | Placebo (N = 73) | Erenumab 70 mg (N = 40) | Placebo (N = 52) | Erenumab 70 mg (N = 90) | Placebo (N = 79) | |
Sex, female, n (%) | 54 (91.5) | 52 (89.7) | 57 (80.3) | 64 (87.7) | 35 (87.5) | 48 (92.3) | 76 (84.4) | 68 (86.1) |
Age, years, mean (SD) | 44.8 (9.5) | 44.9 (8.9) | 43.6 (7.7) | 44.3 (9.7) | 44.4 (9.4) | 44.6 (9.0) | 44.0 (8.2) | 44.5 (9.6) |
Migraine type, n (%) | ||||||||
CM | 30 (50.8) | 31 (53.4) | 22 (31.0) | 19 (26.0) | 18 (45.0) | 24 (46.2) | 34 (37.8) | 26 (32.9) |
EM | 29 (49.2) | 27 (46.6) | 49 (69.0) | 54 (74.0) | 22 (55.0) | 28 (53.8) | 56 (62.2) | 53 (67.1) |
Disease duration, years, mean (SD) | 19.4 (11.2) | 18.4 (10.5) | 16.3 (11.6) | 19.3 (13.1) | 20.7 (12.6) | 19.0 (12.2) | 16.4 (10.8) | 18.8 (11.9) |
MMD, mean (SD) | 13.8 (6.0) | 13.9 (6.0) | 11.2 (5.8) | 10.2 (4.9) | 12.6 (5.9) | 13.0 (6.2) | 12.3 (6.1) | 11.1 (5.3) |
Monthly headache days, mean (SD) | 15.4 (6.6) | 16.1 (6.5) | 12.8 (6.3) | 11.7 (5.6) | 14.4 (6.1) | 14.9 (6.9) | 13.9 (6.7) | 12.8 (5.9) |
Any acute MSM use, n (%) | 57 (96.6) | 55 (94.8) | 68 (95.8) | 69 (94.5) | 39 (97.5) | 48 (92.3) | 86 (95.6) | 76 (96.2) |
Monthly acute MSM treatment days, mean (SD) | 10.6 (6.4) | 10.4 (5.5) | 8.7 (5.3) | 8.3 (4.8) | 9.2 (5.7) | 9.2 (5.4) | 9.7 (6.0) | 9.2 (5.2) |
Prior preventive treatment failure status, n (%) | ||||||||
Never failed (including nonusers) | 0 (0.0) | 0 (0.0) | 71 (100.0) | 73 (100.0) | 18 (45.0) | 24 (46.2) | 53 (58.9) | 49 (62.0) |
Failed ≥1 prior preventive class | 59 (100.0) | 58 (100.0) | 0 (0.0) | 0 (0.0) | 22 (55.0) | 28 (53.8) | 37 (41.1) | 30 (38.0) |
Failed ≥2 prior preventive classes | 30 (50.8) | 33 (56.9) | 0 (0.0) | 0 (0.0) | 12 (30.0) | 15 (28.8) | 18 (20.0) | 18 (22.8) |